Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-168

First 168 Last

Share
Profile

Follow
theplew

501 Posts.

251

24/07/24

14:58

Post #: 74895595
Share

Originally posted by Dowski: ↑

Your analogy goes alright, although you missed out on the reference to both being at the cutting edge of drug development. I expect MSB will finally win their elimination final this year. Win the prelim in 2025 and finally bring home the silverware in 2027. As for the dons, well that's anyone's guess!

The road is long
With many a winding turn
That leads us to who knows where, who knows where
But I'm strong
Strong enough to carry himHe ain't heavy, he's my brother

@Kegarne, this guy, @theplew is my brother, like my brother IRL. Despite him being an Essendon supporter he's still a ripper bloke and I guarantee he's a SH that genuinely wants MSB to succeed as much as you & I but like many has become disillusioned with the big man's loose use of terminology, mainly in reference to timeframes and inflating SH's confidence with terms like "momentous". Patience at an ATL. He wasn't wrong about the Nasdaq and with this potentially playing out over the remainder of 2024, there is plenty of rope for the players to manipulate the SP up and down on the daily as we've already seen today. What I'm very interested in over the coming months is keeping an eye on the shorts. The more they rise, the more likely, IMO, that they'll have to raise at a discount before approval is granted.

The way I see it is there was $76.4mil at June 30 with an $11.7mil spend in previous qtr. I recall SI saying we have stock of Rex-l to complete the trial (someone correct me if I've misheard). Purely spending equivalent $23.4m over next 6 mths (as per Q2) would put cash reserves at $53mil at year end, less any additional costs of preparing the BLA for CHF AA and running the CLBP trial. We recently paid off $10m on one of the loan facilities meaning we need to maintain a cash balance of $30m. I believe with a $23mil buffer to cover the BLA & CLBP costs, we may survive to EOY but it's cutting it way too fine. I am also expecting a partnership deal (or 2) to drop for CHF &/or CBP, once Ryoncil is approved but can we wait that long and risk another CRL? The 4C coming out in the next week will paint a clearer picture but seems like they're going to need to get some cash from somewhere. If a CR, better to raise at these levels than at 30c again.

Expand

Nice of you to associate yourself with such a downramper haha. Maybe we get Danks in to run the show for a bit. Get it things moving.

MSB Price at posting: $1.25 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

HVN

Harvey Norman may appeal ASIC Federal Court case – the third lawsuit on its plate

RBA holds rates as ALP election campaigning kicks off – expect more political focus

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

JDO

Timing will be everything for 'smashing' Hot Stock tip Judo Capital Holdings

There are more pages in this discussion • 217 more messages in this thread...

First 168 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.29		Change 0.005(0.39%)		Mkt cap ! $1.467B

Open	High	Low	Value	Volume
$1.29	$1.31	$1.27	$1.653M	1.285M

Buyers (Bids)

No.	Vol.	Price($)
2	16781	$1.28

Sellers (Offers)

Price($)	Vol.	No.
$1.29	9777	1

View Market Depth

No.	Vol.	Price($)
2	16781	1.280
5	147410	1.275
7	135794	1.270
1	1976	1.265
11	69256	1.260

Price($)	Vol.	No.
1.285	9777	1
1.290	30000	2
1.295	15000	1
1.300	97107	8
1.305	129603	2

Last trade - 16.10pm 05/11/2024 (20 minute delay)

MSB (ASX) Chart

Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-168

Harvey Norman may appeal ASIC Federal Court case – the third lawsuit on its plate

RBA holds rates as ALP election campaigning kicks off – expect more political focus

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Timing will be everything for 'smashing' Hot Stock tip Judo Capital Holdings

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-168

Top Stories

Harvey Norman may appeal ASIC Federal Court case – the third lawsuit on its plate

RBA holds rates as ALP election campaigning kicks off – expect more political focus

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Palladium's the newest geopolitical hot commodity. But ASX exposure is limited

Timing will be everything for 'smashing' Hot Stock tip Judo Capital Holdings

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News